Mergers & Acquisitions ·
Glucotrack, Inc. filed an amendment to its Form 8-K to include financial statements and pro forma information…
GCTKGlucotrack, Inc.
Glucotrack, Inc. filed an amendment to its Form 8-K to include financial statements and pro forma information regarding the reverse merger with Lokahi Therapeutics, Inc., which closed on July 14, 2026. Under the merger terms, Lokahi shareholders received shares of Glucotrack common stock and Series A convertible preferred stock, resulting in Lokahi holders owning 90% of the combined entity's fully diluted equity. The filing includes Lokahi’s unaudited condensed financials for the six months ended June 30, 2026, reporting a net loss of $8,098,087 and cash on hand of $53,186. Additionally, Glucotrack disclosed a confidential settlement agreement executed in April 2026 that resolved disputes with its former parent company, Apimeds Pharmaceuticals US, Inc., involving working capital contributions and the assumption of related party debt. Lokahi Therapeutics is a clinical-stage biopharmaceutical company developing LT-100, a bee venom-based therapy for knee osteoarthritis.